Skip to content

Supernus Pharmaceuticals

Request correction

An award-winning biopharmaceutical company with more than 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases.

Last updated September 1, 2026

AI crawler reads

5requests

1companies
  • Anthropic5
Profile
2
Controversies
2
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

Supernus Pharmaceuticals is an award-winning biopharmaceutical company with more than 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases. The company has eight marketed products that impact patients' lives across migraine prevention, epilepsy, Parkinson's disease, and ADHD, with its launch product Qelbree. Supernus has received numerous awards, including Forbes America's Best Small Companies 2021 and Fortune Magazine's 100 Fastest Growing Companies.

History

Supernus Pharmaceuticals is a biopharmaceutical company with more than 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases. The company has eight marketed products that impact patients' lives across migraine prevention, epilepsy, Parkinson's disease, and ADHD, with its launch product Qelbree. Supernus has received numerous awards, including Forbes America's Best Small Companies 2021 and Fortune Magazine's 100 Fastest Growing Companies.

Controversies

  • 2021

    Supernus sues over Oxtellar XR patents

    Supernus Pharmaceuticals filed suit against Riconpharma and Ingenus, alleging patent infringement connected to their joint abbreviated new drug application for generic oxcarbazepine extended-release tablets. The infringement allegations are claims made by Supernus.

Read more

Recent events

  • Reported

    Supernus sues over Oxtellar XR patents[5]

    Supernus Pharmaceuticals filed suit against Riconpharma and Ingenus, alleging patent infringement connected to their joint abbreviated new drug application for generic oxcarbazepine extended-release tablets. The infringement allegations are claims made by Supernus.

Read more

Sources5 sources

Cite this profile: Cite the canonical profile. /brand-wiki/supernus-pharmaceuticals-united-states · Editorial policy · How profiles are compiled